Actively Recruiting
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
Led by University of Pennsylvania · Updated on 2025-11-19
70
Participants Needed
1
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake in people with MSA with people with Parkinson disease (PD) and progressive supranuclear palsy (PSP) as well as healthy volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (not a clinical site), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.
CONDITIONS
Official Title
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 40 to 80 years
- Men and women clinically diagnosed with Multiple System Atrophy, Parkinson disease, progressive supranuclear palsy, or healthy controls
- Willing and able to provide written informed consent or have a study partner to provide consent and accompany them
- Diagnosis confirmed by consensus committee for PD, MSA, PSP, or healthy control
- Participants asked to agree to brain donation (optional)
You will not qualify if you...
- Pregnant or breastfeeding women
- Diagnosed with forms of parkinsonism other than PD, PSP, or MSA
- History of major psychiatric disorders such as schizophrenia or bipolar disorder (major depressive disorder allowed)
- History of significant or ongoing alcohol or substance abuse
- Unable to tolerate imaging, arterial line, IV placement, or blood draw procedures
- Contraindications to MRI such as incompatible implanted medical devices
- PSP and MSA participants with prior positive beta-amyloid PET scan or positive CSF Alzheimer's disease biomarkers
- Any medical condition or illness that may compromise safety or study participation as judged by a physician or investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin o Schubert
CONTACT
M
Mary Hansbury
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here